# Nicholas P. Restifo

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/nicholas-p-restifo/

## Facts

| Field | Value |
| --- | --- |
| Citations | 97,691 |
| Field | Immunotherapy and Immune Responses |
| h-index | 151 |
| i10-index | 361 |
| Last Known Institution | National Institutes of Health |
| OpenAlex ID | https://openalex.org/A5085899790 |
| Works | 674 |

## Researcher papers

Showing 12 of 14.

- [Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes](https://scholariq.org/papers/cancer-regression-and-autoimmunity-in-patients-after-clonal-repopulation-with/)
- [Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes](https://scholariq.org/papers/cancer-regression-in-patients-after-transfer-of-genetically-engineered/)
- [Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy](https://scholariq.org/papers/durable-complete-responses-in-heavily-pretreated-patients-with-metastatic/)
- [Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma](https://scholariq.org/papers/immunologic-and-therapeutic-evaluation-of-a-synthetic-peptide-vaccine-for-the/)
- [Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma](https://scholariq.org/papers/adoptive-cell-transfer-therapy-following-non-myeloablative-but-lymphodepleting/)
- [Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1](https://scholariq.org/papers/tumor-regression-in-patients-with-metastatic-synovial-cell-sarcoma-and-melanoma/)
- [Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma](https://scholariq.org/papers/cancer-regression-and-autoimmunity-induced-by-cytotoxic-t-lymphocyte-associated/)
- [Identification of essential genes for cancer immunotherapy](https://scholariq.org/papers/identification-of-essential-genes-for-cancer-immunotherapy/)
- [A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response](https://scholariq.org/papers/a-pilot-trial-using-lymphocytes-genetically-engineered-with-an-ny-eso-1-reactive/)
- [Ionic immune suppression within the tumour microenvironment limits T cell effector function](https://scholariq.org/papers/ionic-immune-suppression-within-the-tumour-microenvironment-limits-t-cell/)
- [Super-enhancers delineate disease-associated regulatory nodes in T cells](https://scholariq.org/papers/super-enhancers-delineate-disease-associated-regulatory-nodes-in-t-cells/)
- [Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for Cellular Therapy](https://scholariq.org/papers/mitochondrial-membrane-potential-identifies-cells-with-enhanced-stemness-for/)

## Researcher topics

- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Immune Cell Function and Interaction](https://scholariq.org/topics/immune-cell-function-and-interaction/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [T-cell and B-cell Immunology](https://scholariq.org/topics/t-cell-and-b-cell-immunology/)

## Researcher university

- [National Institutes of Health](https://scholariq.org/institutions/national-institutes-of-health/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.